Resource Center

Media

Dec. 7 Webinar: The Power of Microbial Cell-free DNA: Real World Application of Liquid Biopsy for Endocarditis. Register here

From a single blood sample, the Karius Test can non-invasively and rapidly detect over 1000 pathogens causing both deep-seated and bloodstream infections.

Karius

Pneumonia in the ImmunoCompromised – Use of Karius Test for the Detection of Undiagnosed Pathogens

PICKUP Study

IDWeek Presentation Theater - The Power of Plasma Microbial Cell-Free DNA: Real World Application of a Liquid Biopsy for Infectious Disease

Karius Test - How it Works

Head of User Experience

Karius Portal 2.0

Medical Director

Clinical Overview

Senior Director, Medical Advisor 

A Clinical Lab Perspective

Founder and CSO

Science and Technology

Director of the Kawasaki Disease Clinic Rady Children's Hospital - San Diego

Infections Mimicking Systemic Inflammatory Diseases

Senior Director, Medical Advisor at Karius, Professor Emeritus, Department of Pathology and Laboratory Medicine, Medical University of South Carolina

Enhanced Clinical Metagenomic Testing: A Non-Invasive Liquid Biopsy for Infectious Diseases from Karius

Karius Mobile App - For Clinicians

Assistant Professor and Pediatric Intensivist at the University of California, San Diego and Rady Children's Hospital

Harnessing the Power of Microbial Cell-Free DNA in Plasma with the Karius Test to Detect Critical Infections

Assistant Professor of Medicine Transplant Infectious Diseases University of Colorado

The Karius Test in the Diagnosis and Management of Febrile Neutropenia

Use of the Karius Test in Immunocompromised Patients

Dr. David Berman, Medical Director at Karius, provides an overview of the Karius Test report and examples on how to interpret test results.

Medical Director at Karius

Interpreting the Karius Test Results

Patient Story: Ryan

Patient Story: Brian

The Karius Test® is a liquid biopsy for infection diseases that utilizes microbial cell-free DNA in plasma to detect over 1000 pathogens causing deep-seated and bloodstream infections. During his presentation Dr. Bergin will provide an overview of the Karius multi-center, prospective study comparing the Karius Test to Standard of Care in immunocompromised (IC) patients being evaluated for pneumonia. The population for this study are IC adults with hematological malignancies and/or (HCT) with suspicion of pneumonia. Results are expected later in 2022.

Assistant Professor of Medicine | Director, Fellowship Training Programs Pulmonary Diseases and Critical Care Medicine at Duke University

Pneumonia in the Immunocompromised: Use of the Karius Test®  for the Detection of Undiagnosed Pathogens

Media

Stay up-to-date with Karius